LecB from Pseudomonas aeruginosa modulates Piezo1 currents and localization in a time-dependent manner

Anna-Sophia Kittel1,2,3, Olga Makshakova1,2, Michael Hauerwas1,2

  • 1Faculty of Biology, University of Freiburg, Freiburg, Germany.

Insights

Pseudomonas aeruginosa lectin LecB interacts with the Piezo1 channel, altering its mechanical response. This discovery sheds light on host-pathogen interactions and potential new treatments for antibiotic-resistant infections.

Area of Science:

  • Microbiology
  • Cell Biology
  • Biophysics

Background:

  • Antibiotic resistance in Pseudomonas aeruginosa complicates treatment, leading to impaired host cell functions like migration and wound healing.
  • The bacterial lectin LecB is a key virulence factor mediating host cell adhesion and receptor internalization, but its full impact remains unclear.

Purpose of the Study:

  • To identify novel host cell interaction partners of LecB.
  • To investigate the functional consequences of LecB interaction with host cell proteins.
  • To explore potential therapeutic targets for Pseudomonas aeruginosa infections.

Main Methods:

  • Immunofluorescence and pull-down assays to detect LecB-host protein interactions.
  • Patch-clamp electrophysiology to record Piezo1 channel activity.
  • Computational modeling to predict interaction mechanisms.
  • Inhibition studies using L-fucose and LecB mutants.

Main Results:

  • LecB was identified as an interaction partner of the mechanosensitive ion channel Piezo1.
  • LecB binding altered Piezo1 responses to mechanical stimuli, initially increasing currents and later reducing them.
  • Computational modeling supported direct interactions between LecB and Piezo1, confirmed by functional inhibition experiments.

Conclusions:

  • LecB directly interacts with and modulates the function of the Piezo1 channel.
  • Ion channels and their glycosylation are potential targets for bacterial lectins.
  • This finding advances understanding of host-pathogen interactions and offers a basis for developing new therapeutics against antibiotic-resistant bacteria.